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Abstract
Background: Inspite of introduction of oral hypoglycemic agents, diabetes and its related complications remains to be
a major clinical problem. The aim of this study was to investigate the antidiabetic, antihyperlipidemic and antioxidant
activities of Grewia asiatica (Linn) stem bark in alloxan induced diabetic rats.
Methods: Diabetes was induced by a single dose of intraperitoneal injection of alloxan (110 mg/kg) in Norwegian
Long Evans rats. Ethanol extract of barks from Grewia asiatica (GAE 200 and 400 mg/kg) and metformin (150 mg/kg)
were orally administered once daily for 15 days. Blood glucose levels and body weights of rats were measured on 0, 5,
10 and 15 days of oral treatment. At the end of the experiment the rats were sacrificed and blood sample were
collected for the measurement of total cholesterol (TC), triglycerides (TG), very low density lipoproteins (VLDL),
low density lipoproteins (LDL), high density lipoproteins (HDL), SGOT and CK-MB. Analysis of liver glycogen
content and histopathlogy of pancreas were carried out. In vitro DPPH free radical scavenging activity, total
phenolic and total flavonoid content of GAE were also determined.
Results: After 15 days of oral administration of GAE at doses of 200 and 400 mg/kg increased survival rate and showed
a significant attenuation in blood glucose and lipid profile in diabetic rats. Oral ingestion of GAE significantly reduced
the SGOT and CK-MB levels and restored liver glycogen content when compared to diabetic control. The effects of GAE
on SGOT, CK-MB and liver glycogen content were dose-dependent. The diabetic rats treated with GAE showed
significant improvement in normal cellular population size of islets. Phytochemical screening of GAE revealed the
presence of flavonoid, steroid, tannin and phenolic compounds. Total phenolic content was 44.65 ± 3.17 mg of
gallic acid equivalent per gm of GAE extract and the total flavonoid content was 39.11 ± 4.65 mg of quercetin
equivalent per gm of GAE extract. In DPPH scavenging assay, IC50 values of GAE and ascorbic acid were found 76.
45 and 12.50 μg/ml, respectively.
Conclusion: We demonstrated that ethanol extract of barks from G. asiatica possess glucose, lipid lowering efficacy,
restored liver glycogen and protects pancreas from oxidative damage in alloxan-induced diabetic rats. Thus, the results
of the present study provide a scientific rationale for the use of G. asiatica in the management of diabetes and its
related complications.
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Background
Diabetes mellitus is a metabolic disorder characterized
by loss of glucose homeostasis occurring due to defects
in insulin secretion or insulin action resulting from im-
paired metabolism of glucose, lipids and other energy
yielding fuels such as lipids and proteins [1]. It is a major
endocrine disorder affecting nearly 10 % population all
over the world [2]. Globally diabetes has shadowed the
spread of modern lifestyle and it can be linked to an in-
crease in overweight and sedentary population [3]. Despite
the great strides that have been made in the understand-
ing and management of diabetes, the disease and its re-
lated complications are increasing at an alarming rate [4].
Patients with diabetes have dyslipidemia and an in-
creased risk of stroke, coronary heart disease, myocardial
infarction and peripheral vascular disease [5]. Hypergly-
cemia, the primary clinical manifestations of diabetes is
thought to contribute to diabetic complications by alter-
ing vascular cellular metabolism, vascular matrix mole-
cules and circulating lipoproteins [6]. There are also
multiple abnormalities of lipoprotein metabolism in very
low density lipoprotein (VLDL), low density lipoprotein
(LDL) and high density lipoprotein (HDL) in diabetes. It
is now well established that hyperlipidemia represents a
major risk factor for the premature development of ath-
erosclerosis and its cardiovascular complications [7]. The
American Heart Association (AHA) has identified the pri-
mary risk factor associated with progression of athero-
sclerotic lesions as elevated levels of total cholesterol (TC)
and triglycerides (TG) in serum [8]. So, diabetes is a multi-
factorial diseases leading to several complications require
a multiple therapeutic approach. Many investigations sug-
gested that the medicinal plants and dietary supplements
improves diabetic conditions by lowering lipid and glucose
levels and are useful in the management of diabetic com-
plications especially its associated cardiovascular risks [9].
The most commercially available antidiabetic agents are
expensive and possess undesirable side effects such as po-
tential for induction of hypoglycemia, weight gain, gastro-
intestinal disturbances and liver toxicity [10]. In recent
years, complementary medicines are gaining popularity
worldwide because of their natural origin and less side ef-
fects. Over the years, various medicinal plants have been
reported to be effective in the management of diabetes
mellitus [11]. The hypoglycemic and hypolipidemic effects
of some medicinal plants have been evaluated and con-
firmed in human [12] and animal models [13, 14] and
however, many remained to be scientifically established.
Grewia asiatica L. (Tiliaceae) is an exotic bush plant,
known for its edible ripe fruit which are consumed fresh
[15]. The plant is native to the Indian subcontinent and
now widely cultivated on a commercial scale in India,
Bangladesh, Pakistan, Philippines and other tropical coun-
tries [16]. Traditionally, the plant G. asiatica widely used
for its antidiabetic, antioxidant, antipyretic, analgesic, anti-
bacterial properties [17]. The plant reported to contain
glycoside, flavonoids, vitamins A and C, minerals and
dietary fiber [18–21]. Earlier studies have shown the free
radical scavenging activity and radioprotective efficacy of
G. asiatica fruit extract in brain [22], liver and blood [23].
G. asiatica leaves has been shown to possess hypoglycemic
activity in diabetic rats [24]. Parveen et. al investigated the
comparative anti-hyperglycemic effects of crude ethanolic
extracts of the fruit, stem bark and leaves of G. asiatica
and their fractions in alloxan-induced hyperglycemic rab-
bits after acute treatment [25]. So, we have evaluated the
antidiabetic, hypolipidemic and antioxidant effects of
ethanol extract of stem bark from G. asiatica (GAE) in




The standard drug, Metformin HCl was the generous
gift sample obtained from Square Pharmaceuticals Ltd.,
Pabna, Bangladesh. Alloxan monohydrate was purchased
from Sigma-Aldrich Co. Germany. All other chemical
and solvent used were of analytical grade.
Plant material
The fresh stem barks of the plant G. asiatica were col-
lected from botanical garden of Rajshahi University, Raj-
shahi, during the month of June-July in 2011. The
authenticity of the plant was confirmed and a voucher
specimen collection # 29, dated 06/30/2011 was kept in
the Herbarium, Department of Botany, University of Raj-
shahi, Bangladesh.
Preparation of plant extracts
The collected stem barks were washed, chopped into
small pieces and sun dried for several days. The dried
stem bark grinded to coarse powder after drying in an
oven at below 50 °C. The powdered plant materials were
soaked with 3 L of rectified spirit (96 % ethanol) for 7–10
days with occasional shaking and stirring. The extracts
thus obtained were successively filtered through cotton
and filter paper (Whatman Filter Paper No. 1). The filtrate
was defatted with petroleum ether for several times. The
defatted liquor was concentrated using a rotary evaporator
at 40–45 °C under reduced pressure and finally, the
extract kept into a desiccator to obtain a solid mass (yield
30.0 g; 3.0 %).
Phytochemical screening tests
Detection of phytoconstituents has been performed by
the standard methods [26, 27].
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Animals
Nine-weeks-old Norwegian Long Evans rats (150–180 g)
purchased from ICDDRB, Dhaka, Bangladesh were
housed in cages in an air controlled room under light
and dark cycle conditions. Rats were allowed to access
standard rodent chow and water ad libitum. Throughout
the study the animals were cared in accordance with the
guidelines of our institution. The experimental protocol
was approved by Institutional Animal, Medical Ethics,
Biosafety and Biosecurity Committee (IAMEBBC) at the
Institute of Biological Sciences, University of Rajshahi,
Bangladesh.
Acute toxicity study
The acute oral toxicity study was carried out according
to OECD guidelines. After administration of a fixed dose
of 2000 mg/kg of extract, animals were individually ob-
served for any change in autonomic or behavioral re-
sponse for first 2 h, periodically during first 24 h and
daily thereafter, for a total of 14 days [28].
Induction of experimental diabetes
After fasting 16 h, diabetes was induced into rats by a
single intra-peritoneal (i.p.) injection of alloxan monohy-
drade (110 mg/kg body weight) following base-line glu-
cose estimations. After 96 h blood glucose levels were
measured by glucometer using blood sample obtained
from tail-vein of rat. Rats with blood sugar level higher
than 11.5 mmol/L were considered for the treatment
protocol [29].
Experimental protocol
Twenty diabetic rats were divided into four groups and
each group comprised of five animals. The standard
drugs and/or extracts were suspended in vehicle (0.5 %
methyl cellulose, MC) and administered orally in rats by
gastric tube for 15 days. Age-matched healthy rats were
used as normal control.
1. Normal Control (Group NC, 0.5 % MC, n = 5)
2. Diabetic Control (Group DC, 0.5 % MC, n = 5)
3. Diabetic + Standard Drug (Group DS, Metformin,
150 mg/kg, n = 5)
4. Diabetic + Extract (Group GAE200, 200 mg/kg, n = 5)
5. Diabetic + Extract (Group GAE400, 400 mg/kg, n = 5)
Oral glucose tolerance test (OGTT)
Blood glucose level of rats were measured after fasting
over-night. After 1 h of feeding of extracts and/drugs
rats received glucose solutions (2 g/kg). Blood samples
from each rat were withdrawn from the tail-vein at
0 min, before and after 30, 60 and 120 min of glucose
loading. Plasma glucose levels were estimated using glu-
cose oxidase-peroxidase method [30].
Time course of changes in blood glucose levels
The blood glucose levels of rats were measured on day 0,
before initiation and on 5, 10 and 15 days during the course
of treatment. Blood samples were drawn from the tail-vein
of rats and blood glucose levels were measured [30].
Measurements of body weights and organ weights
The body weights of rats were measured before the initi-
ation and after 15 days of oral treatment. At the end of ex-
periment, the rats were anesthetized, chest opened, blood
samples were withdrawn directly from aorta and poured
into blood collecting tube. The blood samples were centri-
fuged at 4000 rpm for 10 min and the plasma samples
thus, obtained were freeze up at −40 °C until further use.
Heart, liver and pancreases were removed and cleaned of
the surrounding tissues. The organ weights were mea-
sured immediately and the organ weight to body weight
ratios were calculated. Samples of pancreas were stored in
10 % formalin for histopathological examination.
Analysis of lipid profile
Plasma triglycerides (TG), total cholesterol (TC) and high
density lipoprotein (HDL) concentrations were analyzed
by spectrophotometer (Shimadzu 1200, Japan) using com-
mercial kits (Human, Germany). The low density lipopro-
tein (LDL) and very low density lipoprotein (LDL) levels
were determined by the formula, VLDL=TG/5, LDL=TC-
(HDL+VLDL) [31]. The ratios of LDL to HDL cholesterol
were calculated.
Estimation of liver glycogen, SGOT and CK-MB levels
Estimation of CK-MB was done by immuno-inhibition
method as described by the manufacturer protocol [32].
The liver enzyme, serum glutamate oxaloacetate trans-
aminase (SGOT) was determined using commercial kits
(Human, Germany) [33, 34]. The liver glycogen content
was determined according to the method described by
Tarnoky K. et al., [35]. Briefly, it utilizes the o-toluidine-
glucose coupling reaction for the estimation of glycogen
after extraction with trichloroacetic acid (TCA) followed
by precipitation with alcohol and hydrolysis.
Histopathological study
The histopathological studies of liver and pancreas were
carried out at the Department of Pathology, Rajshahi
Medical College, Rajshahi, Bangladesh. Briefly, for light
microscopy liver and pancreas were fixed in PBS con-
taining 10 % formalin. The tissues were washed in run-
ning tap water, dehydrated in the descending grades of
isopropanol and finally cleared in xylene. The tissues
were then embedded in molten paraffin wax. After em-
bedding in paraffin, several transverse sections (5 μm)
were cut from the mid organ level and stained with
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hematoxylin-eosin stain. The specimens were observed
under light microscope at the 400-fold magnification.
In vitro antioxidant activity of GAE extract by DPPH free
radical scavenging assay
The antioxidant property was assessed by DPPH (2, 2-
diphenyl-1-picrylhydrazyl) radical scavenging method
[36]. The hydrogen donating or radical scavenging ability
of the extract was measured using a stable radical
DPPH. 2.8 ml of DPPH solution (45 μg/ml) were rapidly
added in 200 μl of methanol solution of plant extracts at
different concentrations in test tubes. The solutions were
mixed well and then kept in dark for 30 min at room
temperature. The absorbance was measured at 517 nm
in spectrophotometer against methanol solution used as
a blank. Ascorbic acid was used as standard and trolox
in the same concentrations was used as the positive con-
trol corresponding to 100 % radical scavenging activity.
All measurements were done in triplicate.
The percentage (%) of scavenging of the DPPH free
radical was measured by using the following equation:
A0−A1ð Þ=A0f g  100
Where, A0 = absorbance of the control
A1 = absorbance of the extract/standard
Then, the percentage (%) of inhibition was plotted
against log concentration and IC50 was calculated from
the graph.
Determination of total phenolic content in GAE
Total phenol content in extract was determined by Folin-
Ciocalteu reagent [37]. Briefly, the extract (200 μg/ml) was
mixed with 400 μl of the Folin-Ciocalteu reagent and
1.5 ml of 20 % sodium carbonate. The mixture was shaken
thoroughly and made up to 10 ml with distilled water and
after 2 h absorbance of the mixture was measured at
765 nm. The total phenol content in GAE extract was de-
termined from standard curve of gallic acid and was
expressed as mg of gallic acid equivalent per gm of dried
plant extract.
Determination of total flavonoid content in GAE
The total flavonoid content was determined using a
method previously described by Kumaran K [38]. In brief,
1 ml of plant extract in ethanol (200 μg/ml) was mixed
with 1 ml aluminium trichloride in ethanol (20 mg/ml), a
drop of acetic acid was added and then diluted with etha-
nol up to 25 ml. After 45 mins absorbance was measured
at 415 nm against blank. The total flavonoid content in
GAE extract was determined from the standard quercetin
curve and was expressed as mg of quercetin equivalent
per gm of dried plant extract.
Statistical analysis
Data were expressed as means ± standard error of means
(SEM). Statistical comparison was performed by one-way
(ANOVA) followed by Dunnett’s Multiple Comparison
Test. The values were considered as statistically significant
when p <0.05. Statistical calculations and the graph were
prepared using GraphPad Prism Software version 5.0
(GraphPad Software, San Diego, CA, USA).
Results
Acute toxicity study
The oral administration of GAE in rats up to the dose
2000 mg/kg neither exhibit any sign of toxicity nor any
rat died during the 14 days period. It indicates that GAE
was nontoxic in rats up to the oral dose of 2000 mg/kg
body weight. We therefore, carried out our investiga-
tions with 1/5th and 1/10th dose of GAE that is 400 and
200 mg/kg dose levels.
Clinical course
Table 1 shows the survival rate among the group of rats
after 15 days of treatment. Three (60 %) of five rats in
Group DC died between days 7 to 15. None of the rats
died in groups GAE200, GAE400 and DS. The 15 days
survival rate was significantly higher among the treatment
groups than in Group DC (p <0.01).
Effect of GAE on OGTT
After oral ingestion of glucose, the blood glucose levels
were significantly higher among the diabetic rats as shown
in Table 2. In Group DC, blood glucose concentration
were peaked after 30 min and remained high over the next
90 min. Rats in Group GAE200 and GAE400 showed a sig-
nificant attenuation in blood glucose concentration at 60,
90 and 120 min as compared with Group DC rats. How-
ever, the GAE400 showed greater improvement of glucose
tolerance in diabetic rats and was comparable to that of
Group DS (p <0.001).
Table 1 Survival rate of rats after 15 days of oral treatment
Group (n = 5) Total
animal
Survivors Deaths Survival rate (%)
Normal control (NC) 5 5 0 100**
Diabetic control (DC) 5 2 3 40††
Diabetic standard (DS) 5 5 0 100**
GAE 200 (200 mg/kg) 5 5 0 100**
GAE 400 (400 mg/kg) 5 5 0 100**
Data expressed in percentages (%). Control group received 0.5 % methyl
cellulose, standard group received 150 mg/kg Metformin, GAE200 and GAE400
received 200 and 400 mg/kg Grewia asiatica bark extracts. ††p <0.01
compared to NC, **p <0.01 compared to DC
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Time course of changes in blood glucose levels
Time course of changes in blood sugar levels are shown
in Fig. 1. On day 0, before the initiation of treatment the
blood glucose levels were significantly higher in DC rats
compared to NC rats (p <0.01). Oral administration of
GAE significantly lowered the blood glucose levels on
day 5, 10 and 15, and the effect was dose-dependent.
During the course of treatment no significant differences
in blood glucose levels were observed among the treat-
ment groups.
Effect of GAE on body weight and organ weight changes
Body weight, organ weights and organ weight to body
weight ratios are summarized in Table 3. After 15 days
of oral administration of GAE, body weights and organ
weights were decreased in Group DC as compared to
Group NC rats. Although treatment with GAE improved
body weights, organ weights and organ weight to body
weight ratios, the effects were not significant among the
treatment groups.
Effects of GAE extract on lipid profile
Table 4 represents the changes in lipid profile in diabetic
rats. The data revealed that both TC and TG levels were
significantly elevated in Group DC rats. The TC and TG
levels were significantly reduced in Group GAE200 and
GAE400 when compared with Group NC rats. The
plasma HDL level was significantly lower and the levels of
VLDL, LDL and LDL/HDL ratio were significantly higher
in Group DC. Administration of GAE significantly re-
stored the level of VLDL, LDL, HDL and the LDL/HDL
ratio. The effects of GAE on lipid profiles were dose
dependent. Among the extract treated rats, GAE400 ex-
hibited greater improvement in lipid profile.
Effect of GAE extract on liver glycogen, SGOT and
CK-MB levels
The liver glycogen content, SGOT and CK-MB levels in
diabetic rats were shown in Table 5. A significant decrease
in the liver glycogen content was observed in Group DC
rats. The values were significantly restored among the
treatment groups whereby Group GAE400 exerted the
most prominent improvement (p <0.05). After 15 days of
oral ingestion of GAE, the increased level of SGOT and
CK-MB were significantly attenuated in DC rats and was
comparable to that of the NC rats.
Effect of GAE on DPPH free radical scavenging activity
The antioxidant activity of GAE was assessed by in vitro
DPPH free radical scavenging assay. The capability of
GAE on reducing production of DPPH radicals at all
concentrations are shown in Fig. 2. Ascorbic acid, used
as standard was highly effective in inhibiting the DPPH
free radicals, showing an IC50, 12.50 μg/ml where as
GAE exhibited IC50, 76.45 μg/ml.
Phytochemical screening
Phytochemical analysis of the crude extract of G. asiatica
revealed the presence of flavonoid, steroid, glycoside,
saponin, tannin, and triterpinoid (Table 6).
Determination of total phenolic and total flavanoid
content
The total phenol and total flavanoid content are shown
in Table 7. As determined by the spectrophotometer, the
total phenolic content of the extract was 44.65 ± 3.17 mg
Table 2 Effects of GAE on oral glucose tolerance test
Group (n = 5) Time
0 min 30 min 60 min 90 min 120 min
NC 4.8 ± 1.0 8.9 ± 2 6.8 ± 2 6.1 ± 0.8 5.7 ± 1
DC 13.9 ± 1.3††† 18.5 ± 3.5† 15.8 ± 1††† 15.2 ± 1.4††† 14.9 ± 3†††
DS 10.9 ± 1.1† 11.9 ± 1.2 9.8 ± 4* 5.9 ± 0.7*** 5.9 ± 3***
GAE200 12.8 ± 1†† 16.9 ± 1.7† 10.1 ± 1* 9.1 ± 0.8** 7.5 ± 2.1**
GAE400 13.6 ± 1.4††† 19 ± 2.0† 12.3 ± 2* 7.3 ± 0.7*** 7.1 ± 2.5***
Data expressed as means ± SEM. † p <0.05, †† p < 0.01, ††† p < 0.001 compared to NC, *p <0.05, **p <0.01, *** p < 0.001 compared to DC
Fig. 1 Time course of changes in blood sugar levels after oral
administration of GAE in diabetic rats. Data expressed as means ± SEM.
Each group comprised of five animals. NC and DC rats received 0.5 %
MC and DS rats received 150 mg/kg Metformin, GAE200 and GAE400
received 200 and 400 mg/kg Grewia asiatica bark extracts. †p <0.05,
††p <0.01, †††p <0.001 compared to NC, *p <0.05, **p <0.01 and
***p <0.001 compared to DC
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gallic acid equivalents/gm of GAE extract and the total
flavonoid content was 39.11 ± 4.65 mg of quercetin
equivalent/gm of GAE extract.
Histopathological investigation
Figure 3 illustrates representative photographs of thin
sections of pancreas stained with Hematoxylin-eosin,
where NC rats showed normal cellular population in the
islets of Langerhans in pancreas. The islets of diabetic
rats showed extensive damage and inflammations with
loss of normal architecture of pancreatic β-cells. The
rats treated with GAE showed significant improvement
in cellular architecture as observed by the restoration of
normal cellular population size of islets with hyperplasia.
Discussion
Diabetes is multifactorial disease that has a significant ad-
verse impact on health and mortality particularly from
cardiovascular diseases. Now, a day, herbal drugs are gain-
ing popularity in the treatment of diabetes and its related
complications. The present study was designed to assess
the hypoglycemic, hypolipidemic and antioxidant activities
of ethanolic extract of G. asiatica stem barks in alloxan-
induced diabetic rats for 15 days. Alloxan is a hydrophilic
and chemically unstable pyrimidine derivative which can
generate free radicals that are toxic to pancreatic β-cells
causing rapid release of insulin initially and then sharp de-
cline due to excess liberation of stored insulin and in this
study, the diabetogenic effect of alloxan was in accord
with previous studies [39]. Beside insulin, the most widely
used hypoglycemic agents are sulfonylureas and bigua-
nides. However, we choose metformin- a biguanides as a
standard drug which inhibit gluconeogenesis in the liver,
increases affinity to insulin receptors and thus, improve
insulin resistance [40].
The present study indicated that 15 days of oral ad-
ministration of GAE improved survival rate and signifi-
cant reduction in blood glucose, lipids, SGOT, CKMB
levels and restored liver glycogen in diabetic rats. After
Table 3 Changes on body weight and organ weight after oral administration of GAE in diabetic rats
Group (n = 5) Body weight (g) Heart weight (g) Liver weight (g) Pancreas weight (g) H/B (g/kg) L/B g/kg) P/B (g/kg)
NC 150 ± 7 0.48 ± 0.025 5.51 ± 0.47 0.40 ± 0.04 3.1 ± 0.1 35.5 ± 1.23 2.3 ± 0.4
DC 120 ± 6† 0.34 ± 0.025† 3.5 ± 0.22† 0.25 ± 0.02† 2.6 ± 0.2 26.5 ± 2.7† 2.0 ± 0.08
DS 143 ± 7 0.49 ± 0.03 5.1 ± 0.81 0.38 ± 0.04 3.2 ± 0.22 34.2 ± 2.5 2.2 ± 0.26
GAE200 136 ± 6 0.47 ± 0.035 4.23 ± 0.26 0.30 ± 0.03 3.25 ± 0.1 30 ± 1 2.1 ± 0.1
GAE400 130 ± 5 0.45 ± 0.023 4.11 ± 0.25 0.26 ± 0.035 3.3 ± 0.23 30.5 ± 1.1 2.0 ± 0.02
Data expressed as means ± SEM. H/B ratio of heart weight to body weight, L/B ratio of liver weight to body weight, P/B ratio of pancreas weight to body weight.
†p <0.01 compared to NC
Table 4 Changes on lipid profile after oral administration of GAE in diabetic rats
Group (n = 5) Total cholesterol (mg/dl) Triglycerides (mg/dl) VLDL (mg/dl) LDL (mg/dl) HDL (mg/dl) LDL/HDL
NC 70.0 ± 7.4 71.7 ± 6.6† 14.33 ± 4.5 37.6 ± 5.6 29.0 ± 5.7 1.3 ± 0.37
DC 136.7 ± 14.7††† 115.7 ± 5.88††† 23.13 ± 1.1††† 76.3 ± 4.32††† 5.7 ± 1.77††† 13.2 ± 0.6†††
DS 79.0 ± 6.27** 73.5 ± 6.16*** 9.8 ± 6.5*** 25.0 ± 5.56*** 41.5 ± 2.12*** 0.60 ± 0.06***
GAE200 68.3 ± 5.65*** 83.7 ± 5.01** 16.7 ± 1** 18.0 ± 3.74†*** 29.3 ± 3.62*** 0.61 ± 0.08***
GAE400 67.3 ± 8.04*** 77.0 ± 3.74*** 15.4 ± .74** 16.3 ± 2.94†*** 34.3 ± 2.01*** 0.48 ± 0.05***
Data expressed as means ± SEM. † p<0.05, ††† p<0.001 compared to NC, ** p < 0.01, *** p < 0.001 compared to DC
Table 5 Changes on liver glycogen, SGOT and CK-MB levels
after administration of GAE in diabetic rats
Group (n = 5) Glycogen (g/100 g) SGOT (U/l) CK-MB (U/l)
NC 4.60 ± 0.31 8.33 ± 2.48 210 ± 14
DC 1.18 ± 0.57††† 25.0 ± 4.93†† 378 ± 20†††
DS 3.95 ± 0.22*** 9.0 ± 2.30** 185 ± 9***
GAE200 3.42 ± 0.25** 12.0 ± 2.24* 167 ± 11***
GAE400 4.23 ± 0.24*** 7.0 ± 1.7** 152 ± 14***
Data expressed as means ± SEM. ††p <0.01, †††p <0.001 compared to NC, *p
<0.05, **p <0.01, ***p <0.001 compared to DC
Fig. 2 DPPH free radical scavenging activity (%) at various
concentrations (μg/ml) of GAE bark extracts and ascorbic acid
standard. The antioxidant activity of the extract was determined
by the IC50 value
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15 days diabetic rats showed a significant improvement
in glucose tolerance and the effects of GAE on blood sugar
levels and biochemical alterations were dose-dependent.
Remarkably, the rats treated with GAE showed mild to
moderate improvement in cellular architecture as ob-
served by the restoration of normal cellular population
size of islets.
We demonstrated that GAE at the doses of 200 and
400 mg/kg reduced elevated blood sugar level in alloxan-
induced diabetic rats. Our results were in accordance with
outcomes of Parveen et al. showed antihyperglycemic
activity of different parts of G. asiatica in alloxan-induced
rabbits [25]. A number of medicinal plants have been
reported to have an antihyperglycemic activity and a
stimulatory effect on insulin release [41, 42]. The signifi-
cant decrease in the fasting blood glucose levels by GAE
in alloxan diabetic rats may be due to the stimulation of
the residual pancreatic mechanism and probably by
increasing peripheral utilization of glucose or glycogen
synthesis in liver and decreased gluconeogenesis [43].
Induction of diabetes with alloxan is associated with
characteristic loss of body and organ weight, which is
due to increase muscle wasting [44] and loss of tissue
proteins [45]. Diabetic rats treated with GAE showed an
increase in body weight and organ weight which may be
due to protective effect of GAE on tissue structural con-
stituents [46].
Hyperglycemia is accompanied with the increase in
TC, TG, LDL and decrease in HDL which is attributable
to excess mobilization of fat from the adipose due to
under peripheral utilization of glucose [47]. The data re-
vealed that TC, TG, LDL, VLDL levels were significantly
decreased and HDL level increased in diabetic rats treated
with GAE. The Group GAE400 exhibited greater improve-
ment in lipid profile among the treatment groups. Oral
administration of GAE might have improved utilization of
glucose and suppression of lipid mobilizations responsible
for the regression of diabetic state. Further, the effects
may be due to the low activity of cholesterol biosynthesis
enzymes and/or low level of lipolysis which is under the
control of insulin [48]. It is evident that triglycerides are
independent risks factors of coronary heart diseases [49]
and most of the lipid lowering drug does not decrease TG
levels. However, GAE lowered TG levels significantly and
this effect might be due to an increase in endothelium
bound lipoprotein lipase which regulates the disposal of
lipids fuels in the body [50].
The SGOT and CK-MB are sensitive markers of organ
damage [51]. The levels of SGOT and CK-MB were ab-
normally increased alloxan induced diabetic rats. The in-
crease in SGOT levels might be due to hepatotoxicity
and however, the cause of high levels CK-MB remained
to be explained. Oral ingestion of GAE significantly re-
duced SGOT and CK-MB levels among the treatment
groups suggestive of improvement in liver function and
morphology in diabetic rats (Table 5). In our study, in-
duction of diabetes with alloxan was associated with a
marked reduction in liver glycogen stores which could
be attributed to a decrease in the availability of the ac-
tive form of enzyme glycogen synthetase probably be-
cause of low level of insulin [52]. Oral administration of
GAE restored the liver glycogen content possibly due to
an increase level of insulin, which was evident by the
preservation of pancreatic morphology and regeneration
of β-cells (Fig. 3d and e). Vinca rosea extracts and
(−)-Epicatechin have been shown to induce β-cell
Table 6 Phytochemicals of Grewia asiatica stem bark
Extract Alkaloid Glycoside Tannin Triterpene Saponin Flavonoid
GAE − + + + + +
Sign (+) indicates present and sign (−) indicates absent
Table 7 Total phenol and total flavonoid content in Grewia
asiatica stem bark
Scientific name Total phenol content
(mg of gallic acid equivalent
/gm of dried extract)
Total flavonoid content
(mg of quercetin /gm of
dried plant extract)
G. asiatica 44.65 ± 3.17 39.11 ± 4.65
Fig. 3 Hematoxylin-eosin staining of the cross sectional areas of pancreas. Original magnifications 400×. a NC rats showing intact architecture
and normal cellular population of pancreatic β-cells. b DC rats indicating inflammation and damaged islets. c DS rats showing partial restoration
of pancreatic β-cells and absence of islets damage. d GAE 200 showing mild to moderate restoration normal cellular population size of pancreatic
β-cells and absence of islets damage (e) GAE 400 showing maintenance of normal architecture of pancreatic β-cells with hyperplasia
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regeneration in alloxan-induced diabetic rats [53, 54]. In
our studies, the damaged pancreatic β-cells were ob-
served in diabetic rats (Fig. 3b). However, oral ingestion
of GAE restored normal population size of islets by the
regeneration of β-cells (Fig. 3d and e). The antioxidant
activity of the plant extract might play a significant role
in the early recovery of damaged pancreas in diabetic
rats which in turn may be due to the presence of flavon-
oid and phenolic compounds in G. asiatica stem bark.
Conclusion
We concluded that ethanol extract of G. asiatica stem
barks has antidiabetic and lipid lowering efficacy in
alloxan-induced diabetic rats. The plant extract exerts
its beneficial effects by the reduction of blood sugar
levels, lipid profiles, SGOT and restoration of liver glyco-
gen and antioxidant potentials. GAE treated pancreas
showed maintenance of normal architecture of pancre-
atic β-cells as evidenced in histological findings. Thus,
the antihyperglycemic effects of GAE can be partially ex-
plained by their ability to restore the functions of pan-
creatic tissues. However, further histopathological and
biochemical studies are needed to elucidate the exact
mechanism of action of G. asiatica in diabetic rats.
Acknowledgements
The authors would like to express thanks, to Department of Pharmacy,
University of Rajshahi Bangladesh for providing laboratory facilities; Dean,
Faculty of Science, University of Rajshahi for research grants and International
Centre for Diarrhoeal Disease Research, Bangladesh (ICDDRB) for supplying rats
for the research purpose.
Funding
The research work was supported by the grants from Faculty of Sciences,
University of Rajshahi, Rajshahi 6205, Bangladesh. The grants mainly aided us
to design the study protocol and collection of plant materials and
phytochemical tests.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
NAK: collected the plant materials, prepared the extract, carried out all
experiments and drafted the manuscript; MIIW: participated in protocol
design, coordination experimental procedures and revised the manuscript;
BMR: participated in the design and coordinate the anti-oxidant study;
RKB: participated phytochemical testing and statistical analysis of data;
All of the authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Throughout the study the animals were cared in accordance with the
guidelines of our institution. The experimental protocol was approved by
Institutional Animal, Medical Ethics, Biosafety and Biosecurity Committee
(IAMEBBC) at the Institute of Biological Sciences, University of Rajshahi,
Bangladesh.
Received: 22 October 2015 Accepted: 10 August 2016
References
1. Scheen JA. Drug treatment of non insulin dependent diabetes mellitus in
the 1990s achievements and future development. Drug. 1997;54:355–68.
2. Burke JP, Williams K, Narayan KMV, Lelbson C, Haffner SM, Stern MP.
A population perspective on diabetes prevention: whom should we
target for preventing weight gain? Diabetes Care. 2003;26:1999–2004.
3. Vats RK, Kumar V, Kothari A, Mital A, Ramachandran U. Emerging targets for
diabetes. Curr Sci. 2005;88:241–9.
4. Tiwari AK, Madhusudana RJ. Diabetes mellitus and multiple therapeutic
approaches of phytochemicals: present status and future prospects.
Curr Sci. 2002;83:30–8.
5. Brown WV. Lipoprotein disorders in diabetes mellitus. Med Clin North Am.
1994;87:143–61.
6. Stamler I, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors
and 12-yrs cardiovascular mortality for men screened in the multiple risk
factor intervention trial. Diabetes Care. 1993;15:434–44.
7. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG.
Hyperlipidemia in coronary heart disease, genetic analysis of lipid levels in
176 families and delineation of a new inherited disorder, combined
hyperlipidemia. J Clin Invest. 1973;52:1544–68.
8. Kaur J, Singh P, Sowers JR. Diabetes and cardiovascular diseases. Am J Ther.
2002;9:510–5.
9. West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000;
17(3):171–80.
10. Dey L, Anoja MD, Attele S. Alternative therapies for type 2 diabetes. Altern
Med Rev. 2002;7:56–7.
11. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents.
Phytomedicine. 1995;2:137–89.
12. Huang X, Vagg A, Hanson M, Weng J, Goop L. Impaired insulin stimulated
expression of glycogen synthase gene in skeletal muscle of type 2
diabetic patients in acquired rather than inherited. J Chin Endocrinol
Metab. 2000;85:1584–90.
13. Hwang HJ, Kim SW, Lim JM, Joo JH, Kim HO, Kim HM, Yun JW.
Hypoglycemic effect of crude exopolysaccharides produced by medicinal
musroom Phellinus baumii in streptozotocin induced diabetic rats. Life Sci.
2005;76:3069–80.
14. Vinson JA, Zhang J. Black and green teas equally inhibit diabetic cataracts
in streptozotocin induced rat model of diabetes. J Agric Food Chem.
2005;53:3710–3.
15. Salunkhe DK, Desai BB. In: Salunkhe, Desai, editors. Postharvest
biotechnology of fruits; 2. Boca Raton: CRC Press; 1984. p. 129.
16. Hays WB. Fruit Growing in India. 2nd ed. Allahabad: Kitabistan; 1953.
17. Sastri BN. The wealth of India: raw materials. Grewia linn. Tilliaceae Council
of Scientific and Industrial Research, New Delhi, 1956; 4: 260–6.
18. Nair MG, Deueitt DL, Wang H, Krempir D, Wand Mody DK. Dietary food
supplement containing natural cyclooxygenase inhibitors and methods for
inhibiting pain and inflammation US Patent Specification. 2005.
19. Phalsa YAK. In: Janick J, editor. A potential new small fruit for Georgia.
Alexandria: ASHS; 1999. p. 348–52.
20. Gopalan C, Sastri BVR, Balasubramanyam SC. Food composition table
nutritive value of Indian foods. Hyderabad: ICMR; 2002. p. 1–156.
21. Abou Zeid AHS, Sleem AA. Antidiabetic effect and flavonoids of Grewia
asiatica L. Leaves, Dokki, Cairo, Egypt. 2005.
22. Sharma KV, Sisodia R. Evaluation of the free radical scavenging activity and
radioprotective efficacy of Grewia asiatica fruit. J Radiol Prot. 2009;29:429–43.
23. Sisodia R, Singh S, Sharma KV, Ahaskar M. Post treatment effect of Grewia
asiatica against radiation induced biochemical alterations in Swiss albino
mice. J Environ Pathol Toxicol Oncol. 2008;27:113–21.
24. Priyanka P, Patel MM, Bhavsar CJ. Preliminary phytochemical and
hypoglycemic activity of leaves of Grewia Asiatica L. Res J Pharm, Biol Chem Sci.
2011;2(1):516–20.
25. Parvin A, Irfan M, Mohammad F. Antihyperglycemic activity in Grewia
asiatica, a comparative investigation. Int J Pharm Pharm Sci. 2012;4(1):210–3.
26. Pollock JRA, Stevens R. Dictionary of organic compounds, vol. 5. 4th ed.
London: Eyre and Spottishwoode Publishers; 1965.
27. Trease GE, Evans WC. Pharmacognosy. 12th ed. Baillier Tindall: ELBS
Publications; 1996. p. 344–539.
Khatune et al. BMC Complementary and Alternative Medicine  (2016) 16:295 Page 8 of 9
28. OECD (Organization for Economic Co-operation and Development). OECD
Guidelines for the Testing of Chemicals / Section 4: Health Effects Test No.
423: Acute Oral Toxicity - Acute Toxic Class Method. Paris: OECD; 2002.
29. Lenzen S. The mechanisms of action of allxan-and streptozotocin-induced
diabetes. Diabetology. 2008;51:216–26.
30. Bergmeyer HU, Bernayer I, Giabi M, Moss DW. Bergmeyer Methods of
enzymatic analysis 3rd Ed. Overlay Chemical. 1992.
31. Reddy AR, Reddy PG, Venkateshwarlu E, Srinivas N, Nirmala D. Anti-diabetic
and Hypolipidemic effect of Acalypha indica in streptozotocin nicotinamide
induced type -II diabetic rats. Int J Pharm Pharm Sci. 2012;4(2):205–12.
32. Gruber W. Inhibition of creatine kinase activity by Ca+2 and reversing effect
of ethylendiaminetetraacetate. Clin Chem. 1978;24:177.
33. Barnet RN, et al. Protective effects of prostaglandin 12 analogues on super-
oxide induced hepatocyte injury. Am J Clin Path. 1973;59:836.
34. Schumann G, et al. IFCC primary reference procedures for the measurement of
catalytic activity concentrations of enzymes at 37 °C. International Federation
of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for
the measurement of catalytic concentration of aspartate aminotransferase. Clin
Chem Lab Med. 2002;40(7):725–33.
35. Tarnoky K, et al. Spectrophotometric determination of glycogen with
O-toluidine. Clin Chem Acta. 1963;8:627–8.
36. Yen G-C, Chen H-Y. Antioxidant activity of various tea extracts in relation to
their antimutagenicity. J Agric Food Chem. 1995;43:27–32.
37. McDonald S, Prenzler PD, Autolovich M, Robards K. Phenolic content and
antioxidant activity of olive oil extracts. Food Chem. 2001;73:73–84.
38. Kumaran K. Estimation of total flavonoid content in propolis by two
complementary colorimetric methods. J Food Drug Anal. 2007;10(3):178–82.
39. Szkudelski T. The Mechanism of alloxan and streptozotocin action in β-cells
of the rat pancreas. Physiol Res. 2001;50:536–46.
40. Goth A. Medical pharmacology: principles and concepts. 9th ed. St. Louis:
CV Mosby Company; 1978.
41. Pari L, Latha M. Effect of Cassia auriculata flowers on blood sugar alevels,
serum and tissue lipids in streptpzotocin diabetic rats. Singapore Med J.
2002;43:617–21.
42. Lee MK, Kim MJ, Cho SY, et al. Hypoglycemic effect of Du-zhong (Eucommia
ulmoids Oliv.) leaves in streptozotocin- induced diabetic rats. Diabetes Res
Clin Pract. 2005;67:22–8.
43. Khan BA, Abraham A, Leelamma S. Hypoglycemic action of Murraya koengii
(curry leaf) and Brussia juncea (mustard): mechanism of action. Indian J
Biochem Biophys. 1995;32:106–8.
44. Swanston-Flat SK, Day C, Bailley CJ, Flatt PR. Traditional plant treatment for
diabetes: studies in normal and streptozotocin diabetic mice. Diabetologia.
1990;33:462–4.
45. Chatterjea MN, Shinde R. Diabetes mellitus. In: Text book of medical
biochemistry. New Delhi: Jaypee Brothers Medical publishers; 2002. p. 317.
46. Whitton PD, Hems DA. Glycogen synthesis in perfused liver of
Streptozotocin diabetic rats. Biochem J. 1975;150:153–9.
47. Krishnakumar K, August KT, Vijayammal PL. Hypolipidemic effect of Salacia
oblonga Wall. Root bark in Streptozotocin diabetic rats. Med Sci Res. 2000;28:65–7.
48. Sharma SB, Nasir A, Prabhu KM, Murthy PS, Dev G. J Ethnopharmacol.
2003;85:201–6.
49. Bainton D, Miller NE, Botton CH, Yarnell JW, Sweetnam PM, Baker IA, Lewis B,
Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol a
predictors of ischemic heart disease in Britain man. Br Heart J. 1992;68:60–6.
50. Taskimen MR. Lipiprotin lipase in diabetes. Diabetes Metab Rev. 1987;3:551–70.
51. Ghosh S, Suryawanshi SA. Effect of Vinca rosea extracts in treatment of
alloxan diabetes in male albino rat. Ind J Exp Biol. 2001;39:748–59.
52. Garvey WT. Glucose transport and NIDDM. Diabetes Care. 1992;15:396–417.
53. Chakravarthy BK, Gupta S, Gode KD. Functional beta cell regeneration in the islets of
pancreas in alloxan induced diabetic rats by (−)-epicatechin. Life Sci. 1982;31:2693–7.
54. Gorray KC, Baskin D, Brodsky J, Fujimoto WY. Responses of pancreatic b cells
to alloxan and streptozotocin in the guinea pig. Pancreas. 1986;1:130–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Khatune et al. BMC Complementary and Alternative Medicine  (2016) 16:295 Page 9 of 9
